Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
139.79
-2.95 (-2.07%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novo Nordisk A/S ADR
< Previous
1
2
3
Next >
Voyager Therapeutics stock pops 30% on deal with Novartis
January 08, 2024
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took
Via
MarketBeat
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
January 08, 2024
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.
Via
MarketBeat
Topics
ETFs
Is the January Effect reliable indicator for yearly performance?
January 04, 2024
The January Effect refers to January’s market return as predictive of the full year. But is January's performance truly an indicator of how the year may go?
Via
MarketBeat
Topics
ETFs
Weight Watchers gains from Oprah’s GLP-1 weight-loss
January 02, 2024
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
LifeMD expands telehealth GLP-1weight-loss service with Medifast
December 19, 2023
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing
Via
MarketBeat
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
December 06, 2023
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication
Via
MarketBeat
Ozempic vs. Mounjaro:: Battle of the bulge
December 04, 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage
Via
MarketBeat
Exposures
Product Safety
Watch the buy range for Li Auto, MongoDB, Novo Nordisk
November 29, 2023
Large-cap stocks Li Auto, MongoDB, and Novo Nordisk are in buy range as the S&P 500 rallies. Those stocks boast robust upside momentum in recent weeks
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
BellRing Brands gets pumped on the Ozempic weight-loss trend
November 27, 2023
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss
Via
MarketBeat
Will Eli Lilly's Zepbound be the next big weight-loss drug?
November 10, 2023
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion
Via
MarketBeat
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
October 25, 2023
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
October 19, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Is the Ozempic-Driven DexCom Selloff Overdone?
October 18, 2023
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly?
Via
MarketBeat
Snack Maker Mondelez Int'l Is Down but Not Out
October 16, 2023
If Mondelez beats consensus for Q3 and can offer reassurance about the potential impact of Ozempic, investors’ appetite for chewed up snack makers may improve.
Via
MarketBeat
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
October 12, 2023
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products.
Via
MarketBeat
Obesity Drug Boom, Split Make This Stock a Heavy Bargain
October 09, 2023
Ozempic users may be losing their appetites for sweets…but Novo Nordisk is one Danish treat that the market may only get hungrier for.
Via
MarketBeat
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
September 19, 2023
Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline
Via
MarketBeat
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
MarketBeat Week in Review – 8/7 - 8/11
August 12, 2023
The latest inflation readings failed to provide clarity for investors as stocks had a turbulent week and the MarketBeat team was covering the top stories
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
August 09, 2023
Novo Nordisk's stock surged 16% on preliminary results of clinical trials showing its weight-loss drug Wegovy reduces risk of cardiovascular disease by 20%.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.